BioSpace News Archive

– Supports the investigation of TransCon hGH for treatment of growth hormone deficiency in the pediatric population from 6 months to less than 18 years of age – – Company on track to submit European marketing application in third quarter 2020 – – No additional studies required – COPENHAGEN, Denmark, July 06, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, tod

A-Medicare, the flagship private health services entrepreneurial enterprise of actor-producer Enzo Zelocchi, today announced launch plans for a new crypto coin as a planned element of early strategic growth integral to platform development through the remainder of 2020 and 2021.

CardieX Limited (ASX: CDX, CardieX, the Company) 100% subsidiary ATCOR has submitted a US patent application in regards to its recently announced wearable sensor technology (ASX: 24/04/2020).

ReadCoor, Inc., a company leading true multi-omic spatial sequencing, announced the appointment of Dennis Flannelly to its Board of Directors.

Paragonix Technologies, Inc . announced the presentation of new clinical data at the American Transplant Congress (ATC) on the successful use of the Paragonix SherpaPak™ Cardiac Transport System (CTS) for high-risk donor hearts at the Medical University of Vienna - Allgemeines Krankenhaus Wien

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the start of a prospective, observational, global, multi-center, real-world, post-market study to evaluate the safety and effectiveness of the Valiant Navion™ Thoracic Stent Graft System in the treatment of thoracic aort

HOYA Corporation (TSE:7741, “HOYA”) and Hitachi, Ltd. (TSE:6501, “Hitachi”) today announced a five year contract regarding Endoscopic Ultrasound Systems [EUS] by which, i) the parties will strengthen technical collaboration, and ii) Hitachi will continue supplying diagnostic ultrasound systems and ultrasound sensor related parts used in EUS.

Deloitte has appointed Asif Dhar, M.D., to lead its life sciences and health care (LSHC) practice in the United States effective immediately.

Acquisition includes lead clinical-stage compound PLX9486, a potent and selective KIT D816V inhibitor Company positioned to advance best-in-class precision kinase inhibitors Proceeds of $104.4 million to be used to advance clinical testing in mastocytosis and GIST Conference call today at 10:30 a.m. EDT

The Journal of Vascular and Interventional Radiology’s (JVIR’s) Impact Factor—one measure of a journal’s influence based on the number of article citations compared to the total number of citable articles published—has broken 3 for the first time.